SLC6A19 and cancer: Pan-cancer mutation prognosis analysis showed that ACE1 and TMPRSS2 mutations were associated with better survival in cancer patients (Supplementary Figure 3; p = 0.0273 and 1.18e−10), whereas mutated SLC6A19 was associated poor survival in cancer patients (Supplementary Figure 3; p = 1.47e−4).